Atropos Health, based in Palo Alto, California, has announced significant advancements in its oncology precision medicine capabilities. The company has published new artificial intelligence (AI) algorithms designed for monitoring paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder. This expansion builds on previous AI tools aimed at improving early diagnosis, further enhancing patient care for individuals already diagnosed with PNH.
These newly developed algorithms focus on tracking disease progression in PNH patients. They aim to reduce the risk of severe complications, including thrombosis, organ dysfunction, anemia, and worsening hemolytic anemia. Health systems can now access these AI monitoring tools to provide better patient outcomes.
Dr. Sandeep Jain, Director of Medical Innovation in Hematology and Oncology at Atropos Health, will present findings on this innovation at the ASH Annual Meeting in Orlando, Florida. His presentation, titled “Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data,” is scheduled for December 7, 2025. The poster session, “803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II,” will take place from 18:00 to 20:00 in room OCCC – West Halls B3-B4.
In addition to the new AI algorithms, Atropos Health has integrated the American Society of Clinical Oncology (ASCO) guidelines into its platform. This integration equips oncologists and researchers with the latest evidence-based treatment and care recommendations, facilitating personalized patient care. The Atropos platform now allows physicians to easily access ASCO Guidelines, which play a crucial role in guiding treatment decisions.
“The future of evidence-based medicine in oncology is being transformed by data and technology,” said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. He emphasized that the combination of integrating ASCO guidelines with the publication of new AI models represents a significant step toward advancing precision medicine. By making these tools accessible and public, Atropos Health aims to empower clinicians to navigate complex patient pathways with enhanced clarity and deliver personalized, evidence-driven care.
This announcement follows the recent launch of Atropos Evidence™, an expert agent designed to generate real-world evidence (RWE). Atropos Health is currently embedding personalized evidence within electronic health records (EHR) at Stanford Health Care, utilizing data from ChatEHR to improve RWE at the point of care. In collaboration with Microsoft, the company plans to combine ambient encounter data from Dragon Copilot with the Atropos Evidence™ agent.
Founded with the mission to transform healthcare using timely, relevant real-world evidence, Atropos Health develops GENEVA OS®, an operating system that bridges the gap between clinical data and patient care. Healthcare and life science organizations partner with Atropos Health to enhance patient outcomes through data-driven approaches while advancing medical research.
For more information about Atropos Health, visit their website at www.atroposhealth.com, connect on LinkedIn, or follow them on X @AtroposHealth.
